on Pentixapharm Holding AG (isin : DE000A40AEG0)
Pentixapharm Holding AG Announces Leadership Changes
Berlin, Germany, October 25, 2024 - Pentixapharm Holding AG has announced significant changes in its management and supervisory boards, effective at the end of October 2024. Dr. Hakim Bouterfa, the founder and CEO, will step down from his management roles to join the Supervisory Board, following a nomination by major shareholder Eckert Wagniskapital und Frühphasenfinanzierung GmbH.
Nuclear medicine expert Prof. Dr. Ken Herrmann will join the Supervisory Board, replacing physicist Paola Eckert-Palvarini. Meanwhile, Dr. Andreas Eckert will temporarily serve as Executive Chairman, with Frank Perschmann as Chairman of the Supervisory Board.
Dr. Dirk Pleimes has been appointed as CEO of Pentixapharm AG, continuing his role as Chief Medical Officer. These adjustments mark the end of the company's spin-off from Eckert & Ziegler SE, with full details available soon on the company's website.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Pentixapharm Holding AG news